AMARANTH Clinical Trial

The AMARANTH Clinical Trial Research Study

Mild Cognitive Impairment (MCI) / Early Alzheimer’s Disease

Principal Investigator: James Mastrianni, MD, PhD 
Clinical Trials Coordinator: Breanna Bertacchi, BA

Status: Enrolling

The University of Chicago Memory Center for Comprehensive Care and Research on Memory Disorders is currently enrolling individuals ages 55 to 85 years, with early Alzheimer’s disease (patients with mild cognitive impairment due to Alzheimer’s disease and patients diagnosed with mild dementia of the Alzheimer’s type) to participate in the clinical trial AMARANTH to help us examine an investigational drug that may have some effect on the brain changes associated with Alzheimer’s disease.

The purpose of the study is to find out whether this investigational drug can influence the decline in memory and mental functioning. “Investigational” means that the drug has not been approved for clinical use, and is being evaluated in clinical studies.

The study treatment is an oral tablet to be taken once a day. The tablet will contain either the investigational drug or a placebo, depending on which group you are randomly assigned. If you are already receiving standard treatments for Alzheimer’s disease, in most cases, these can be continued during the study.

The AMARANTH Study involves more than 1500 participants from around 175 study memory centers like our own, in 15 countries worldwide.

Duration: The study will last for approximately 24 months (about 8 weeks to see if you qualify, plus 2 years of treatment, then 4-6 weeks of follow-up).

To join this study you must:

  • Be between 55 and 85 years old

  • Have either: Experienced gradual and progressive change in memory function over more than 6 months (the study team will assess whether this is due to Alzheimer’s disease)  OR  Been diagnosed with mild Alzheimer’s disease or mild cognitive impairment (MCI)

  • Have a relative, friend or caregiver who would be willing to be your study partner throughout the study

  • Meet additional study criteria

The principal investigator, James Mastrianni, MD, PhD, and our clinical trials coordinator, Breanna Bertacchi, will explain any potential risks and benefits to you and will describe the study procedures before you decide to join the study.

To learn more about this study, please contact:
Breanna Bertacchi at 773-834-1688